Advertisement

Topics

Triumvira Immunologics Company Profile

08:16 EST 16th December 2018 | BioPortfolio

Triumvira is developing an engineered T-cell technology called the T-Cell Antigen Coupler (TAC), developed in the laboratory of Dr. Jonathan Bramson at McMaster University in Hamilton, Ontario, and is designed to activate T-cells through the T-cell receptor complex. In multiple liquid and solid tumor animal models, TAC-T cells outperform CAR-T cells, with markedly improved pharmacodynamic effects and reduced toxicity. The company aims to enter the clinic a year from now, and is focusing its pipeline expansion on solid tumor targets. Not only does the TAC-T platform offer best-in-class potential, but the novel structure provides freedom to operate in a crowded space.


News Articles [12 Associated News Articles listed on BioPortfolio]

Triumvira Immunologics Names Donna Rill Chief Technology Officer

Triumvira Immunologics, an Austin, TX-based biotech, appointed Donna Rill to serve as chief technology officer. Triumvera said Rill will use her technology development and manufacturing experience to ...

Triumvira licenses antibodies from University of Toronto

The University of Toronto granted Triumvira Immunologics Inc. exclusive rights to antibodies for use in the development of T-cell therapeutics for cancer.

Triumvira Immunologics Appoints Scott Smith to Board of Directors

Innovative immuno-therapy company welcomes former President and COO of Celgene Triumvira Immunologics, Inc., a privately held biopharmaceutical company developin...

Triumvira Immunologics Announces Presentation of Key Preclinical Data on TAC Technology at American Society of Hematology

Triumvira Immunologics, Inc. (Triumvira), announced the upcoming presentation of key preclinical data at the American Society of Hematology (ASH) 60th Annual Meeting and Expositio...

Triumvira Hires Donna Rill as Chief Technology Officer

Brings 30-years of Experience to Company’s Technology Development and Manufacturing Operations Triumvira Immunologics, a privately held biopharmaceutical company deve...

CCAB And Triumvira Immunologics Announce Triumvira’s License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates

The Centre for the Commercialization of Antibodies and Biologics (CCAB) and Triumvira Immunologics, Inc. (Triumvira), announced today a new licensing agreement between the

Triumvira Immunologics Demonstrates Prolonged TAC-T Cell Persistence and Efficacy in Preclinical Models

New Preclinical Data Presented at Annual Meeting of American Society of Hematology Triumvira Immunologics Inc. (Triumvira), announced the presentation of key preclinica...

Triumvira Presents Data on T Cell Antigen Coupler (TAC) Technology at the 6th Annual Immuno-Oncology Summit

TAC technology shows efficacy, safety, and TAC-T cell persistence in preclinical models of liquid and solid tumors Triumvira Immunologics, Inc. (Triumvira), a privately...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [6 Associated Companies listed on BioPortfolio]

Triumvira Immunologics, Inc.

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the...

Triumvira Immunologics Inc.

Triumvira Immunologics, Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., a niche life-sciences investment...

Triumvira Immunologics

Triumvira is developing an engineered T-cell technology called the T-Cell Antigen Coupler (TAC), developed in the laboratory of Dr. Jonathan Bramson at McMaster University in Hami...

Signature Immunologics

Signature Immunologics produces anti-hapten IgGs for High Performance Immunocytochemistry (HPI), targeting key small molecules in cell physiology, including fast neurotransmitter amino acids and pivot...

Quantum Immunologics, Inc.

More Information about "Triumvira Immunologics" on BioPortfolio

We have published hundreds of Triumvira Immunologics news stories on BioPortfolio along with dozens of Triumvira Immunologics Clinical Trials and PubMed Articles about Triumvira Immunologics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Triumvira Immunologics Companies in our database. You can also find out about relevant Triumvira Immunologics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record